The collaboration addresses the logistical hurdles inherent in the radiopharmaceutical sector, where strict safety and quality standards must be maintained during transit. By utilizing Jubilant Radiopharma’s specialized infrastructure, AtomVie aims to enhance the reliability of its clinical development programs. This agreement covers the full spectrum of distribution, ensuring that products manufactured at AtomVie’s 72,300-square-foot Hamilton facility reach their destinations with precision.
In section Releases
AtomVie and Jubilant Radiopharma Form Logistics Alliance
Hamilton-based AtomVie Global Radiopharma has entered a strategic agreement with Jubilant Radiopharma to manage the complex supply chain demands of clinical radiopharmaceutical trials. The partnership leverages Jubilant’s extensive U.S. pharmacy network to oversee regulatory compliance, handling, and the critical last-mile delivery of time-sensitive therapeutic products to clinical sites.
AtomVie CEO Bruno Paquin noted that the partnership is vital for supporting the company’s expanding portfolio and meeting the rigorous demands of global clinical trials. Harsher Singh, CEO of Jubilant Radiopharma, emphasized that the move aligns with his firm’s existing footprint in nuclear medicine, providing the regulatory expertise and national delivery capabilities required to accelerate patient access to emerging therapies.
Comments (0)
No comments yet. Be the first!